S20

Semaglutide 20mg

Each order comes with five Syringes, Alcohol pads, and 3ml BAC water.

Semaglutide is a once-weekly injectable or oral medication primarily used for the treatment of type 2 diabetes and obesity. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics the effects of GLP-1 to regulate blood sugar levels, reduce appetite, and promote weight loss.

For research purposes only.

Mechanism of Action:

Stimulates insulin secretion in response to elevated blood sugar.

Suppresses glucagon release, reducing glucose production in the liver.

Delays gastric emptying, leading to increased satiety and reduced food intake.

Acts on the brain's appetite centers, decreasing hunger and food cravings.

Uses:

Type 2 Diabetes Treatment (brand names Ozempic and Rybelsus).

Weight Management (brand name Wegovy).

Potential Cardiovascular Benefits, as some studies suggest it reduces heart disease risks.

Benefits:

Lowers A1C levels in people with type 2 diabetes.

Leads to significant weight loss, with some patients losing over 15% of body weight.

May reduce risks of heart attack and stroke in high-risk individuals.

Side Effects:

Common: Nausea, vomiting, diarrhea, constipation, and decreased appetite.

Serious: Pancreatitis, gallbladder disease, kidney issues, and potential thyroid tumors (based on animal studies).

Comparison to Other GLP-1 Drugs (e.g., Tirzepatide):

Semaglutide acts only on GLP-1 receptors, while tirzepatide targets both GLP-1 and GIP receptors, potentially enhancing weight loss and blood sugar control.

Some studies suggest tirzepatide leads to greater weight loss compared to semaglutide.

Dosage & Administration:

Ozempic (Injection): Weekly injection for type 2 diabetes.

Rybelsus (Oral): Daily tablet form for type 2 diabetes.

Wegovy (Injection): Higher-dose weekly injection for weight loss.

Who Should Avoid It?

Individuals with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2).

Those with a history of pancreatitis or severe gastrointestinal disorders.

For research purposes only.